Friday, April 25, 2014

GeneNews’ JV lab launches phi test in U.S.

GeneNews’ JV lab launches phi test in U.S.

April 24, 2014 by · Leave a Comment 

Tweet GeneNews’ (TSX:GEN) recently formed joint venture, Innovative Diagnostic Laboratory, has added Beckman Coulter Diagnostics’ Prostate Health Index (phi) to its menu of advanced cancer assays and has initiated a commercial roll out of the groundbreaking test across the U.S. The phi test is a simple, non-invasive blood test that is three times more specific […]

Novadaq to acquire Aimago S.A.

Novadaq to acquire Aimago S.A.

April 24, 2014 by · Leave a Comment 

Tweet Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) has agreed to acquire all outstanding shares of Aimago S.A., a closely held medical imaging company, founded in 2008 as a spin off from Ecole Polytechnique Federale de Lausanne, a Swiss-based academic and research institution. Aimago’s lead product, the EasyLDI Perfusion Camera, incorporates patented, high-speed, full field laser Doppler technology. […]

Cynapsus reports positive study data for APL-130277

Cynapsus reports positive study data for APL-130277

April 24, 2014 by · Leave a Comment 

Tweet Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH) has released positive data from its recently completed CTH-104 healthy volunteer pilot study of a single, 25-milligram sublingual strip (APL-130277) dose of apomorphine. APL-130277 is an easy-to-administer, fast-acting reformulation of apomorphine, which is the only approved drug in the U.S., Europe, Japan and other countries for the acute rescue of […]

Feltl starts Evoke Pharma at strong buy

Feltl starts Evoke Pharma at strong buy

April 22, 2014 by · Leave a Comment 

Tweet Feltl & Co. has initiated coverage of Evoke Pharma (NASDAQ:EVOK) with a “strong buy” rating and $16 price target. The stock was quoted at $9.33, up $1.47, in late trading on Tuesday. Evoke will be initiating a Phase 3 trial with its EVK-001 in the current quarter, targeting women with diabetic gastroparesis. EVK-001′s intranasal […]

Stem Cell Therapeutics graduates to TSX

Stem Cell Therapeutics graduates to TSX

April 22, 2014 by · Leave a Comment 

Tweet Stem Cell Therapeutics (OTCQX:SCTPF; TSX:SSS) said its common shares have been approved for listing on the Toronto Stock Exchange and began trading at the opening today. The company’s common shares have been delisted from the TSX Venture Exchange. “Graduation to the TSX is one of several important corporate milestones we aim to achieve this […]

Alcon’s Paul Smith joins TearLab as VP International

Alcon’s Paul Smith joins TearLab as VP International

April 21, 2014 by · Leave a Comment 

Tweet TearLab (NASDAQ:TEAR; TSX:TLB) has appointed Paul Smith to its senior management team in the newly created position of VP, International. Mr. Smith’s mandate will be the development and execution of a comprehensive international business strategy for TearLab. He joins TearLab from his current position as global marketing manager within the surgical cataract franchise at […]

Roth and Cantor start Applied Genetics at buy

Roth and Cantor start Applied Genetics at buy

April 21, 2014 by · Leave a Comment 

Tweet Roth Capital Partners and Cantor Fitzgerald have initiated coverage of Applied Genetics Technologies (NASDAQ:AGTC) at “buy” ratings, with price targets of $25 and $21, respectively. The stock closed at $14.08 on Thursday. Applied Genetics is a gene therapy company with a focus on orphan ophthalmology and lung disorders. The company uses its adeno-like virus […]

Veteran banker Michael Mandel has joined Brean Capital

Veteran banker Michael Mandel has joined Brean Capital

April 16, 2014 by · Leave a Comment 

Tweet Brean Capital has recently hired veteran healthcare investment banker, Michael Mandel, as managing director of the firm based in New York. Mr. Mandel has over 17 years of experience in healthcare investment banking and has successfully closed over 60 financing and M&A transactions for private, large and small/mid cap public companies with aggregate transaction […]

Cynapsus completes $25-million financing

Cynapsus completes $25-million financing

April 15, 2014 by · Leave a Comment 

Tweet Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH) has completed the sale of 38,461,538 units at a price of 65 cents each for gross proceeds of $25-million.  Each unit consists of one common share and one warrant.  Each warrant can be exercised to purchase an additional common share during the next 60 months. The offering was led by M Partners […]

Roth starts AcelRx Pharma at buy

Roth starts AcelRx Pharma at buy

April 14, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of AcelRx Pharmaceuticals (NASDAQ:ACRX) with a “buy” rating and $22 price target. The stock closed at $10.32 on Friday. “We believe Zalviso is a disruptive technology that will transform the way many hospitals treat patients with moderate-to-severe acute pain, primarily in the postoperative setting, by providing a solution demonstrated to […]

Next Page »

Google+